These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 4006340)

  • 21. Effect of amiodarone in the Wolff-Parkinson-White syndrome.
    Wellens HJ; Lie KI; Bär FW; Wesdorp JC; Dohmen HJ; Düren DR; Durrer D
    Am J Cardiol; 1976 Aug; 38(2):189-94. PubMed ID: 952262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of intravenous diltiazem administration in patients with inducible tachycardia.
    Waleffe A; Hastir F; Kulbertus HE
    Eur Heart J; 1985 Oct; 6(10):882-90. PubMed ID: 4076199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional properties of accessory atrioventricular pathways in Wolff-Parkinson-White syndrome. Clinical implications.
    German LD; Gallagher JJ
    Am J Med; 1984 Jun; 76(6):1079-86. PubMed ID: 6731464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
    Swerdlow CD; Peterson J; Liem LB
    Am J Cardiol; 1988 Jul; 62(1):78-82. PubMed ID: 2898208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D; Rowland E; O'Nunain S; Shakespeare CF; Poloniecki J; Camm AJ
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transesophageal versus intracardiac atrial stimulation in assessing anterograde conduction properties of the accessory pathway in Wolff-Parkinson-White syndrome.
    Favale S; Minafra F; Massari V; Tritto M; Rizzon P
    Int J Cardiol; 1991 Feb; 30(2):209-14. PubMed ID: 2010244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long term use of flecainide in patients with supraventricular tachycardia.
    Neuss H
    Drugs; 1985; 29 Suppl 4():21-5. PubMed ID: 4006776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion of supraventricular arrhythmias to sinus rhythm using flecainide.
    Goy JJ; Grbic M; Hurni M; Finci L; Maendly R; Duc J; Sigwart U
    Eur Heart J; 1985 Jun; 6(6):518-24. PubMed ID: 4043101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation.
    Kappenberger LJ; Fromer MA; Steinbrunn W; Shenasa M
    Am J Cardiol; 1984 Aug; 54(3):330-5. PubMed ID: 6465013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical electrophysiologic effects of lorcainide in patients and its effect on the conduction of accessory pathway in Wolff-Parkinson-White syndrome].
    Jiang H
    Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Jun; 18(3):157-9, 190. PubMed ID: 2086169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and electrophysiologic characteristics in patients with Wolff-Parkinson-White pattern.
    Antunes E; da Silva N; Catarino C; Serra J; Galrinho A; Ferreira R; Quininha J; Gracias R; Rato JA
    Rev Port Cardiol; 1993 Apr; 12(4):333-6. PubMed ID: 8512728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome.
    Rinkenberger RL; Naccarelli GV; Miles WM; Markel ML; Dougherty AH; Prystowsky EN; Heger JJ; Zipes DP
    Am J Cardiol; 1988 Dec; 62(19):26L-30L. PubMed ID: 3144164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of intravenous flecainide on atrial vulnerability in man.
    Pop T; Treese N; Kang JC; Meinertz T; Kasper W
    Klin Wochenschr; 1983 Jun; 61(12):609-15. PubMed ID: 6876690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome.
    Manolis AS; Estes NA
    Am J Cardiol; 1989 Jul; 64(3):194-8. PubMed ID: 2500840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome.
    Crijns HJ; den Heijer P; van Wijk LM; Lie KI
    Am Heart J; 1988 Jun; 115(6):1317-21. PubMed ID: 3132032
    [No Abstract]   [Full Text] [Related]  

  • 36. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds.
    Hellestrand KJ; Nathan AW; Bexton RS; Camm AJ
    Am J Cardiol; 1984 Feb; 53(5):30B-38B. PubMed ID: 6695817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
    Orning OM
    Eur Heart J; 1984 Sep; 5 Suppl B():81-6. PubMed ID: 6437821
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome.
    Morady F; DiCarlo LA; Baerman JM; De Buitleir M
    Pacing Clin Electrophysiol; 1987 May; 10(3 Pt 1):492-6. PubMed ID: 2439997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiological studies in patients with the Wolf-Parkinson-White syndrome.
    Farré J; Ross DL; Wiener I; Bär FW; Vanagt E; Wellens HJ
    Herz; 1979 Feb; 4(1):38-46. PubMed ID: 437670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings.
    Hu J; Yu J; Chen Q; Hu J; Huang Q; Xia Z; Xia Z; Ju Z; Yuan P; Fan S; Xiong Q; Zhu B; Huang L; You C; Bao H; Wu Y; Cheng X; Li J; Marian AJ; Hong K
    J Am Heart Assoc; 2019 Jul; 8(13):e012511. PubMed ID: 31234695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.